Start with coverage, not brand. If a health plan covers anti-obesity medication, the service that fights hardest for prior authorization wins on cost. If the plan excludes the category, the choice collapses into a self-pay comparison and speed matters more than paperwork. Medical history then narrows the shortlist further, sometimes down to a single labeled product.
Input one: what the benefit document says
Before opening any signup flow, find the plan formulary and search for the anti-obesity category. Employer plans differ enormously, individual marketplace plans follow state benchmark decisions, and Medicare drug benefits have long excluded agents prescribed only for weight reduction. That single lookup determines which of these services is even relevant.
Where coverage exists, both Ro and Calibrate build their offer around getting a claim approved. Ro publishes a free insurance check and an insurance concierge that files prior authorization paperwork. Calibrate positions insurance navigation as a core service, with staff working the initial GLP-1 prescription through existing coverage. Where coverage does not exist, that machinery still runs, produces a denial, and leaves the buyer paying a self-pay price weeks later than they would have otherwise.
Input two: how quickly the first dose needs to arrive
Timelines diverge sharply. Calibrate’s published onboarding runs an eligibility quiz, an intake form, baseline blood work at a lab, and a clinician video visit reviewing those results roughly one to two weeks in. Ro’s process includes a benefit verification stage before shipment. Hims and Hers, having moved to approved brand products through a manufacturer arrangement announced in March 2026, quotes self-pay medication prices directly, which shortens the path when a shopper is not pursuing coverage.
Neither approach is superior in the abstract. A person with generous coverage and no urgency should tolerate the benefits process, because the savings dwarf a few weeks of waiting. A person who already knows their plan excludes the category is paying for a workflow that cannot help them.
Existing relationships with a provider can also shape the choice. A shopper already refilling an ED treatment through HealthRX, or using Hims and Hers or Ro for the same, may prefer to keep weight care under one login, whereas Calibrate and Henry Meds tend to be single-purpose destinations. Convenience of that kind is legitimate, though it should be weighed against price and product rather than allowed to settle the question on its own.
Input three: whether coaching is worth a line item
Calibrate is the outlier of the three on service design. It sells a metabolic health program: recurring short one-to-one video coaching, a structured curriculum, baseline labs, and a program arc extending past twelve months, with the medication billed separately. Hims and Ro are medication-first platforms where messaging, dose support and check-ins wrap around a prescription rather than constituting the product.
Behavioral support does have an evidence base. Trials pairing medication with intensive behavioral therapy show additive effect, and reviews of GLP-1 adherence associate structured nutritional and lifestyle support with staying on treatment. What the evidence does not support is treating coaching as equivalent to the drug. Someone who has repeatedly stopped medication early may get real value from the accountability layer, and someone who simply wants a reliable prescription refilled is paying for a service they will not open.
For that second reader, the flat cash market is worth pricing. Programs publishing a single monthly figure that covers clinician oversight and the medication together, including Henry Meds, Mochi Health and the provider behind it, allow arithmetic before checkout, though they generally dispense compounded preparations that the FDA has not reviewed for safety, effectiveness or manufacturing quality.
Input four: the medical history that narrows the label
Some histories point at one product rather than one platform. Zepbound carries a second indication for moderate to severe obstructive sleep apnea in adults with obesity, so a documented sleep apnea diagnosis changes both the clinical argument and the coverage argument. A type 2 diabetes diagnosis moves the conversation toward products labeled for glycemic control, since Mounjaro is indicated for glycemic control in adults and pediatric patients aged ten and older with type 2 diabetes, and Ozempic sits in the same column.
Other histories close doors. The labels in this class carry a boxed warning regarding thyroid C-cell tumors, with contraindications for personal or family history of medullary thyroid carcinoma and for multiple endocrine neoplasia syndrome type 2. History of pancreatitis, significant gastrointestinal disease, gallbladder disease and diabetic retinopathy all belong in the intake honestly, because a program cannot screen for what it is not told. Pregnancy and attempts to conceive are their own conversation and belong with a treating clinician rather than an intake form.
| Decision input | Points toward a coaching and navigation program | Points toward medication-first telehealth | Points toward flat cash compounded |
|---|---|---|---|
| Plan covers the category | Strong fit, navigation does the work | Strong fit, concierge files paperwork | Weak fit, coverage goes unused |
| Plan excludes the category | Weak fit, fee buys unusable service | Moderate fit, self-pay prices published | Strong fit if pathway is understood |
| History of stopping early | Strong fit, accountability is the product | Moderate fit | Weak fit, minimal support layer |
| Sleep apnea or type 2 diabetes | Depends on which labeled product is reachable | Depends on which labeled product is reachable | Weak fit, compounded products carry no approved labeling |
| Speed to first dose | Slower, labs and visit precede treatment | Moderate, benefit check precedes shipment | Fastest in most cases |
| Wants approved brand product only | Yes, brand products are the route | Yes, brand pens and tablets published | No |
A short sequence that settles most cases
Check the formulary. Get a clinical diagnosis list in writing, including sleep apnea and diabetes status. Decide whether the coaching layer solves a problem that has actually occurred before. Then price the total monthly outlay at the maintenance dose under both the covered and uncovered scenarios. Most people find that two of the three options fall away before any signup page loads.
Frequently asked questions
Is a coaching program worth paying for on top of the drug?
It depends on the failure mode being solved. Behavioral support shows real but moderate independent effect in trials, and it tends to help most where adherence has broken down before. Someone who has never struggled to continue a prescription is buying a service that duplicates something they already do without help.
Can a program guarantee access to a specific brand product?
Not reliably. Product availability depends on the prescribing clinician’s judgment, the pharmacy channel, the plan’s formulary tier and any manufacturer arrangement the platform holds. Asking which specific products the program has dispensed recently, and from which pharmacy, produces a more useful answer than asking what it can prescribe in principle.
Does an obstructive sleep apnea diagnosis change the decision?
It can. One tirzepatide product carries an approved indication for moderate to severe obstructive sleep apnea in adults with obesity, which gives both the clinician and the plan reviewer a labeled reason for that specific product. Documenting the diagnosis before intake is worth doing rather than mentioning it in passing later.
What history should be disclosed even if it seems unrelated?
Thyroid cancer in the family, endocrine tumor syndromes, prior pancreatitis, gallbladder problems, significant gastrointestinal disease, eye disease related to diabetes and any current GLP-1 prescription from another source. Labels in this class carry contraindications and warnings tied to several of those, and an incomplete intake removes the screen that exists to catch them.
